PURPOSE: To detect localized glaucomatous structural changes using proper orthogonal decomposition (POD) framework with false-positive control that minimizes confirmatory follow-ups, and to compare the results to topographic change analysis (TCA). METHODS: We included 167 participants (246 eyes) with ≥4 Heidelberg Retina Tomograph (HRT)-II exams from the Diagnostic Innovations in Glaucoma Study; 36 eyes progressed by stereo-photographs or visual fields. All other patient eyes (n = 210) were non-progressing. Specificities were evaluated using 21 normal eyes. Significance of change at each HRT superpixel between each follow-up and its nearest baseline (obtained using POD) was estimated using mixed-effects ANOVA. Locations with significant reduction in retinal height (red pixels) were determined using Bonferroni, Lehmann-Romano k-family-wise error rate (k-FWER), and Benjamini-Hochberg false discovery rate (FDR) type I error control procedures. Observed positive rate (OPR) in each follow-up was calculated as a ratio of number of red pixels within disk to disk size. Progression by POD was defined as one or more follow-ups with OPR greater than the anticipated false-positive rate. TCA was evaluated using the recently proposed liberal, moderate, and conservative progression criteria. RESULTS: Sensitivity in progressors, specificity in normals, and specificity in non-progressors, respectively, were POD-Bonferroni = 100%, 0%, and 0%; POD k-FWER = 78%, 86%, and 43%; POD-FDR = 78%, 86%, and 43%; POD k-FWER with retinal height change ≥50 μm = 61%, 95%, and 60%; TCA-liberal = 86%, 62%, and 21%; TCA-moderate = 53%, 100%, and 70%; and TCA-conservative = 17%, 100%, and 84%. CONCLUSIONS: With a stronger control of type I errors, k-FWER in POD framework minimized confirmatory follow-ups while providing diagnostic accuracy comparable to TCA. Thus, POD with k-FWER shows promise to reduce the number of confirmatory follow-ups required for clinical care and studies evaluating new glaucoma treatments. (ClinicalTrials.gov number, NCT00221897.).
PURPOSE: To detect localized glaucomatous structural changes using proper orthogonal decomposition (POD) framework with false-positive control that minimizes confirmatory follow-ups, and to compare the results to topographic change analysis (TCA). METHODS: We included 167 participants (246 eyes) with ≥4 Heidelberg Retina Tomograph (HRT)-II exams from the Diagnostic Innovations in Glaucoma Study; 36 eyes progressed by stereo-photographs or visual fields. All other patient eyes (n = 210) were non-progressing. Specificities were evaluated using 21 normal eyes. Significance of change at each HRT superpixel between each follow-up and its nearest baseline (obtained using POD) was estimated using mixed-effects ANOVA. Locations with significant reduction in retinal height (red pixels) were determined using Bonferroni, Lehmann-Romano k-family-wise error rate (k-FWER), and Benjamini-Hochberg false discovery rate (FDR) type I error control procedures. Observed positive rate (OPR) in each follow-up was calculated as a ratio of number of red pixels within disk to disk size. Progression by POD was defined as one or more follow-ups with OPR greater than the anticipated false-positive rate. TCA was evaluated using the recently proposed liberal, moderate, and conservative progression criteria. RESULTS: Sensitivity in progressors, specificity in normals, and specificity in non-progressors, respectively, were POD-Bonferroni = 100%, 0%, and 0%; POD k-FWER = 78%, 86%, and 43%; POD-FDR = 78%, 86%, and 43%; POD k-FWER with retinal height change ≥50 μm = 61%, 95%, and 60%; TCA-liberal = 86%, 62%, and 21%; TCA-moderate = 53%, 100%, and 70%; and TCA-conservative = 17%, 100%, and 84%. CONCLUSIONS: With a stronger control of type I errors, k-FWER in POD framework minimized confirmatory follow-ups while providing diagnostic accuracy comparable to TCA. Thus, POD with k-FWER shows promise to reduce the number of confirmatory follow-ups required for clinical care and studies evaluating new glaucoma treatments. (ClinicalTrials.gov number, NCT00221897.).
Authors: Madhusudhanan Balasubramanian; Christopher Bowd; Robert N Weinreb; Gianmarco Vizzeri; Luciana M Alencar; Pamela A Sample; Neil O'Leary; Linda M Zangwill Journal: Invest Ophthalmol Vis Sci Date: 2009-08-06 Impact factor: 4.799
Authors: Andrew J Patterson; David F Garway-Heath; Nicholas G Strouthidis; David P Crabb Journal: Invest Ophthalmol Vis Sci Date: 2005-05 Impact factor: 4.799
Authors: Christopher Bowd; Madhusudhanan Balasubramanian; Robert N Weinreb; Gianmarco Vizzeri; Luciana M Alencar; Neil O'Leary; Pamela A Sample; Linda M Zangwill Journal: Invest Ophthalmol Vis Sci Date: 2008-10-03 Impact factor: 4.799
Authors: Akram Belghith; Christopher Bowd; Felipe A Medeiros; Madhusudhanan Balasubramanian; Robert N Weinreb; Linda M Zangwill Journal: Artif Intell Med Date: 2015-04-23 Impact factor: 5.326
Authors: Akram Belghith; Christopher Bowd; Felipe A Medeiros; Madhusudhanan Balasubramanian; Robert N Weinreb; Linda M Zangwill Journal: J Med Imaging (Bellingham) Date: 2014-12-29
Authors: Madhusudhanan Balasubramanian; Ery Arias-Castro; Felipe A Medeiros; David J Kriegman; Christopher Bowd; Robert N Weinreb; Michael Holst; Pamela A Sample; Linda M Zangwill Journal: Invest Ophthalmol Vis Sci Date: 2014-03-19 Impact factor: 4.799
Authors: Akram Belghith; Madhusudhanan Balasubramanian; Christopher Bowd; Robert N Weinreb; Linda M Zangwill Journal: Comput Med Imaging Graph Date: 2014-03-13 Impact factor: 4.790
Authors: Siamak Yousefi; Madhusudhanan Balasubramanian; Michael H Goldbaum; Felipe A Medeiros; Linda M Zangwill; Robert N Weinreb; Jeffrey M Liebmann; Christopher A Girkin; Christopher Bowd Journal: Transl Vis Sci Technol Date: 2016-05-03 Impact factor: 3.283
Authors: Akram Belghith; Felipe A Medeiros; Christopher Bowd; Jeffrey M Liebmann; Christopher A Girkin; Robert N Weinreb; Linda M Zangwill Journal: Invest Ophthalmol Vis Sci Date: 2016-07-01 Impact factor: 4.799